Fig. 4From: Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stromaG-CSF treatment reduced the clonogenic capacity of AML bulk population. Primary patient AML samples were treated with G-CSF as indicated for 18 h. a CFU-B were counted based on morphological criteria. b Relative change in the clonogenic capacity after G-CSF treatment in patients who achieved a complete response after induction treatment (CS) compared to primary chemorefractory patients (CR). Each symbol corresponds to an AML patient. All data was normalized against control. *p < 0.05, **p < 0.01, ***p < 0.001Back to article page